An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime

Novo Nordisk A/S2,134 enrolled

Overview

This study is conducted in Europe. The aim of this study is investigate the potential of a supplementary insulin therapy regimen (SIT) as intensification for insufficiently controlled patients with type 2 diabetes in a normal diabetes care setting.

Study Type

OBSERVATIONAL

Enrollment

2,134

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

insulin aspartDRUG

Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)

insulin detemirDRUG

Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * OAD monotherapy * OAD combination therapy * Therapy with OAD and basal insulin * Conventional insulin therapy with premixed insulin

Locations (1)

Unnamed facility

Mainz, Germany

Outcomes

Primary Outcomes

HbA1c (glycosylated haemoglobin)

Secondary Outcomes

Fasting blood glucose (FBG)

2-hours postprandial blood glucose

Hypoglycemia

Weight development

Adverse Drug Reactions (ADRs) including Serious Adverse Drug Reactions (SADRs)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.